Dynavax Technologies Corporation (DVAX) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Dynavax (DVAX) Q3 2025: HEPLISAV-B Market Share Hits 46% as Pipeline and Capital Return Accelerate
November 06, 2025
-
Dynavax (DVAX) Q2 2025: Hepatitis B Market Share Climbs to 45% as Retail Channel Accelerates
August 08, 2025
-
Dynavax (DVAX) Q1 2025: HEPLISAV-B Jumps 36% as Retail Channel Drives Market Share Expansion
July 06, 2025